Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.
Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.